Immix Biopharma IMMX
NASDAQ IMMX
$8.66 +0.31 (+3.71%)
At close: Nov 11, 2026 · 4:00 PM EST

Immix Biopharma (IMMX) Net Income Attributable to Noncontrolling Interests (2023 - 2026)

Updated

Immix Biopharma (IMMX) posted Income from Non-Controlling Interests of -$84,987 for FY2024, compared with -$169,474 in FY2023.

Analysis

Immix Biopharma (IMMX) Net Income Attributable to Noncontrolling Interests (2023 - 2026) Analysis & Trends

  • Business Quant data shows IMMX's Income from Non-Controlling Interests at -$169,474 in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -1.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 10.00 Mn
10 Immix Biopharma 597.32 Mn 365.22 Mn - 13.08 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 13.08 Bn
Mar 31, 2026 45,476.00
Jun 30, 2025 49.57 Bn
Mar 31, 2025 16,519.00
Jun 30, 2024 -12,914.00
Mar 31, 2024 -72,073.00
Dec 31, 2023 -65,862.00
Sep 30, 2023 -63,248.00
Jun 30, 2023 -21,996.00
Mar 31, 2023 -18,368.00
API Access

Immix Biopharma Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=IMMX&period=max&api_key=YOUR_API_KEY